1. The value of Treat-to-target and early remission in RA and interpreting clinical evidence with Upadacitinib 2. The safety profile of Upadacitinib in RA 3. Real-world persistence of Upadacitinib in RA 4. Bridging evidence and clinical practice: My experience on clinical decision-making with Upadacitinib